GLP-1 Cost 2026: Brand, Self-Pay & Cash

Last reviewed: May 12, 2026 Last updated: May 12, 2026

Written by: Jay Hastings , CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — your resource for evidence-based guidance on GLP-1 therapies, weight management protocols, and the genetic variables that shape every metabolic decision. Browse all Peptides & GLP-1 education

If you have searched “GLP-1 cost” in 2026 you have already learned that the same medication can cost $25 a month for one patient and $1,349 a month for the next. The active ingredient is identical — what changes is the pricing pathway. Insurance coverage, manufacturer self-pay programs (Lilly Direct, NovoCare), Medicare rules, and cash-pay compounded telehealth all sit on top of the same molecules and produce wildly different out-of-pocket totals. This guide walks the actual numbers for Wegovy, Ozempic, Zepbound, and Mounjaro at brand list price, what each manufacturer’s direct self-pay program charges, what compounded GLP-1s cost through telehealth providers, and how PlexusDx Weight Management Protocols — from Microdose GLP-1 Protocol at $129/mo to Tirzepatide Oral at $279/mo — fit on the cost map. The goal is not to talk you into one path; the goal is to make sure the number you commit to is the number you can actually sustain for 12 months.

What “GLP-1 cost” actually means in 2026

There are four distinct pricing layers in the U.S. GLP-1 market and most cost confusion comes from people comparing across layers without realizing it. Layer 1 is the manufacturer list price (WAC, or wholesale acquisition cost) — what an uninsured walk-up patient would theoretically be billed at retail. Layer 2 is commercial-insurance copay pricing — what a covered patient pays after deductible and savings card stacking, often $25–$100/month. Layer 3 is the manufacturer’s direct self-pay program — Lilly Direct (Zepbound) and NovoCare (Wegovy, Ozempic) sell the FDA-approved branded product directly to cash-pay patients at a discounted but still meaningful monthly fee. Layer 4 is cash-pay compounded GLP-1 through telehealth platforms — the same active ingredients (semaglutide, tirzepatide) prepared by licensed compounding pharmacies and sold without going through a brand. PlexusDx Weight Management Protocols sit in Layer 4. The right comparison for a cash-pay patient is almost always Layer 3 vs Layer 4, not Layer 1 vs anything.

Branded GLP-1 list prices — the headline numbers

These are the WAC numbers manufacturers publish and that headlines quote. They are real prices, but they are rarely what an actual patient pays. Wegovy pen (semaglutide, FDA-approved for chronic weight management): $1,349.02 per 28-day package, per Novo Nordisk. Wegovy pill (oral semaglutide for weight management): $1,349.02 per 28-day package. Ozempic pen (semaglutide, FDA-approved for type 2 diabetes): $1,027.51 per pen package. Zepbound pen (tirzepatide, FDA-approved for chronic weight management): approximately $1,086.37 WAC for a 28-day carton of four pens. Mounjaro pen (tirzepatide, FDA-approved for type 2 diabetes): roughly $1,080 WAC for a 28-day carton. Note the manufacturer convention: a “month” in WAC pricing means 28 days (four weekly pens), not a calendar month. Across a calendar year that adds roughly 4–5% to the implied annual cost. At list price, an uninsured year on any of these branded products lands between $13,000 and $16,500.

Manufacturer self-pay programs — Lilly Direct and NovoCare

Both major GLP-1 manufacturers operate direct self-pay channels that bypass the pharmacy benefit manager and offer the FDA-approved branded product to cash-pay patients at a discount. Lilly Direct sells Zepbound vials (not pens) at tiered pricing: $299/month for the 2.5 mg starting dose, $399/month for 5 mg, and $449/month for 7.5 mg through 15 mg, when the patient meets refill timing rules. Lilly Direct also offers a Zepbound pen savings program at as low as $499/month for commercially insured patients without coverage. NovoCare (Novo Nordisk’s direct-to-patient program) advertises Wegovy pen self-pay at $199/month for the first two fills for new patients within a limited window, then $349/month thereafter, and Wegovy pill self-pay at $149/month for the 1.5 mg and 4 mg doses (with a documented offer change after April 15, 2026) and $299/month for the 9 mg and 25 mg doses. NovoCare also offers Ozempic at $199/month for the first two fills then $349/month for the 0.25, 0.5, and 1 mg doses, or $499/month for the 2 mg dose. Annual totals on these programs land between roughly $1,800 and $5,400 — a real reduction from list price, but most patients still find the math difficult to sustain past the first 90 days. Manufacturer savings programs typically exclude Medicare, Medicaid, VA, and TRICARE beneficiaries by their published terms.

Cash-pay compounded GLP-1 — the fourth pricing layer

Compounded semaglutide and tirzepatide are pharmacy-prepared versions of the same active ingredients used in Wegovy, Ozempic, Zepbound, and Mounjaro. They are not FDA-approved as finished drug products — only the branded versions are — but they are prepared under U.S. compounding regulations by licensed pharmacies and dispensed via prescription from licensed clinicians. Telehealth platforms have built cash-pay subscription pricing around compounded GLP-1s: typical advertised pricing in early 2026 ranges from roughly $129/month for entry-tier microdose protocols to $300–$600/month for higher-dose injectable tirzepatide. The annualized cost on most compounded telehealth programs lands between $1,500 and $4,000 — below the manufacturer self-pay programs and well below WAC. The trade-offs to weigh: compounded products lack the FDA finished-product approval, supply consistency depends on the pharmacy, and the boxed warning for thyroid C-cell tumors that applies to branded semaglutide and tirzepatide based on rodent studies applies to the compounded versions as well.

How the PlexusDx Weight Management Protocols are priced

PlexusDx offers six prescription compounds across four mechanism classes — tirzepatide, semaglutide, microdose, and dual-compound — with all-inclusive pricing that covers the async provider consultation, the prescription, the compounded medication itself, and shipping. Five states require a scheduled live consultation; the rest run async. There is no membership fee. The full lineup:

Microdose GLP-1 Protocol — $129/mo flat. Compounded GLP-1 in four delivery formats (capsule, troche, lozenge, sublingual). Lowest entry point in the lineup, useful for needle-averse patients or starter dosing. $1,548/year.
Semaglutide Injection — $149/mo. Compounded weekly semaglutide, 0.25 mg to 2.0 mg across five dose levels. The closest cash-pay analog to Wegovy or Ozempic. $2,148–$2,748/year.
Semaglutide Oral — from $249/mo. Compounded oral semaglutide, 3 mg to 24 mg daily across six dose levels. Closest cash-pay analog to Rybelsus or the Wegovy pill.
Tirzepatide Injection — $249/mo. Compounded weekly tirzepatide GIP/GLP-1 dual-agonist, 2.5 mg to 15 mg across six dose levels. Cash-pay analog to Zepbound or Mounjaro. $2,748–$3,708/year.
Tirzepatide Oral — $279/mo. Compounded oral tirzepatide, 5 mg to 25 mg daily across seven dose levels. The non-injection tirzepatide path.
GLP-Squared — $249/mo. Compounded semaglutide + tirzepatide dual-compound therapy across six provider-titrated dose pairs. $2,148–$3,900/year.

The optional Precision Peptide Genetic Test is $298 standalone or $99 as an add-on after the first month on any protocol. It maps 48 genes, 57 variants, and 14 health pathways — including 34 weight-management insights and the GIPR rs1800437 variant linked to differential GLP-1 response — so the prescribing clinician can anchor titration decisions to a measurable genetic baseline rather than starting from population averages.

Annual cost comparison — what 12 months actually adds up to

For a cash-pay patient with no GLP-1 coverage, here is what one year on each pathway looks like at typical doses, before any pharmacy or shipping surcharges. Wegovy pen at WAC: roughly $16,188/year. Zepbound pen at WAC: roughly $13,032/year. NovoCare Wegovy pen self-pay: $199 + $349 × 11 = $4,038/year (assuming the limited-window introductory pricing). NovoCare Wegovy pill self-pay (1.5 mg): $1,788/year. Lilly Direct Zepbound vials: $299 × 12 (2.5 mg) = $3,588/year, or $449 × 12 (7.5–15 mg) = $5,388/year. PlexusDx Microdose GLP-1 Protocol: $129 × 12 = $1,548/year. PlexusDx Semaglutide Injection: $2,148–$2,748/year. PlexusDx Tirzepatide Injection: $2,748–$3,708/year. PlexusDx Tirzepatide Oral: $2,748–$6,108/year depending on dose level. The pattern: if your insurance covers Wegovy or Zepbound at a low copay, that path wins. If it does not, the comparison narrows to NovoCare/Lilly Direct vs cash-pay compounded — and at the entry tiers, the compounded pathway tends to be 30–60% lower annually than the manufacturer’s own self-pay program for the same active ingredient.

Medicare, Medicaid, and the 2026 CMS GLP-1 demonstration

Medicare Part D historically excluded coverage of weight-loss medications, which has constrained access for older patients. In 2026, CMS announced a GLP-1 payment demonstration and the BALANCE model aimed at expanding access and lowering costs, with published materials referencing beneficiary out-of-pocket costs under $50/month for eligible participants — though the actual numbers depend on participation and program eligibility rules that are still being finalized. The 2026 Medicare Part D structure also raised the maximum deductible to $615 and capped annual out-of-pocket spending at $2,100, which materially reduces the worst-case exposure for any covered medication. The catch: most manufacturer savings programs exclude Medicare, Medicaid, VA, and TRICARE beneficiaries, so the path to a low monthly cost on the branded product runs through Part D coverage and the new CMS demonstration rather than through Lilly Direct or NovoCare. Cash-pay compounded telehealth (including PlexusDx Weight Management Protocols) is available to Medicare-eligible patients on a self-pay basis — the PlexusDx pricing above applies regardless of Medicare status.

The hidden costs most cost guides skip

Headline monthly pricing rarely captures the full year. A few items to budget for regardless of pathway: follow-up visits — on PlexusDx these are included in the all-inclusive monthly fee; on branded retail pathways, the prescribing clinician’s office visits are separate. Lab work — baseline metabolic panels and periodic re-checks are clinically appropriate on GLP-1s and not always covered. Side-effect management — anti-nausea medication, electrolyte support, and the occasional dose-pause week add small recurring costs. Refill timing rules — Lilly Direct’s Zepbound vial pricing depends on refilling within a defined window; missing the window can shift you to a higher tier. Dose escalation — budget assuming you will titrate up; the price at month one is rarely the price at month nine. Genetic testing — if dose decisions matter to you, the Precision Peptide Genetic Test at $99 as an add-on after your first PlexusDx month adds a measurable baseline to the titration conversation.

Frequently asked questions

How much do GLP-1 medications cost per month in 2026?

It depends on the pathway. Manufacturer list prices for Wegovy, Ozempic, Zepbound, and Mounjaro range from roughly $1,027 to $1,349 per 28-day package, but commercial-insurance copays can land at $25–$100/month, manufacturer self-pay programs (Lilly Direct, NovoCare) range $149–$499/month, and cash-pay compounded telehealth runs roughly $129-$369/mo. PlexusDx Weight Management Protocols span $129-$369/mo across the full lineup.

What is the cheapest legitimate brand-name GLP-1 option without insurance?

NovoCare lists Wegovy pill self-pay at $149/month for the 1.5 mg and 4 mg doses (with documented offer changes after April 15, 2026), and Lilly Direct sells Zepbound vials at $299/month for the 2.5 mg starting dose with refill-timing rules. Which is cheapest in your situation depends on what is medically appropriate and how long you stay at the lower dose.

How much does Wegovy cost in 2026 without insurance?

Wegovy’s list price is $1,349.02 per 28-day package, but Wegovy.com describes self-pay pricing options including $349/month for the pen (after $199/month introductory pricing for the first two fills) and dose-based self-pay pricing for Wegovy pill at $149–$299/month.

How much does Zepbound cost without insurance?

Zepbound’s WAC for pens is approximately $1,086.37 for a 28-day carton of four pens, but Lilly Direct sells Zepbound vials at $299/month (2.5 mg), $399/month (5 mg), and $449/month (7.5–15 mg) with refill-timing rules, and the Zepbound pen savings program can be as low as $499/month for commercially insured patients without Zepbound coverage.

Do manufacturer savings cards work with Medicare?

No. Manufacturer savings programs typically exclude government-program beneficiaries, including Medicare, Medicaid, VA, and TRICARE, per the published terms on Lilly Direct and NovoCare savings pages. The 2026 CMS GLP-1 payment demonstration is the path most likely to reduce out-of-pocket cost for Medicare-eligible patients.

Is compounded GLP-1 from a telehealth platform legal and safe?

Telehealth prescribing is legal when performed by appropriately licensed clinicians and fulfilled by appropriately licensed compounding pharmacies. Compounded semaglutide and tirzepatide are not FDA-approved finished products, so quality and supply consistency depend on the pharmacy. The boxed warning for thyroid C-cell tumors that applies to branded semaglutide and tirzepatide based on rodent studies applies to compounded versions as well. Vet the provider and pharmacy.

How does PlexusDx pricing compare to Lilly Direct and NovoCare?

PlexusDx Weight Management Protocols range from $129/mo on the Microdose GLP-1 Protocol to $509/mo at the highest Tirzepatide Oral dose, with all-inclusive pricing that covers the async provider consultation, prescription, compounded medication, and shipping. At the entry and mid tiers, PlexusDx sits below NovoCare Wegovy pen self-pay ($349/mo) and Lilly Direct Zepbound mid-dose vials ($399–$449/mo) for the same active ingredients in compounded form. PlexusDx is cash-pay, no membership, available in all 50 states (five require a live consult).

GLP-1 Cost (2026): Branded List Prices, Self-Pay Programs and Cash-Pay Alternatives | PlexusDx